scPharmaceuticals Inc.

NasdaqGS SCPH

scPharmaceuticals Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024

scPharmaceuticals Inc. Net Income is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

scPharmaceuticals Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -35.84 M, a -25.76% change year over year.
scPharmaceuticals Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -28.50 M, a 19.12% change year over year.
scPharmaceuticals Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -35.24 M, a -29.17% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqGS: SCPH

scPharmaceuticals Inc.

CEO	Mr. John H. Tucker
IPO Date	Nov. 17, 2017
Location	United States
Headquarters	2400 District Avenue
Employees	135
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Drugstores & Retail Pharmacies Non-Alcoholic Beverages

Description

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Key trends

Past 5 years